Recombinant Human Erythropoietin
Mostrando 1-12 de 77 artigos, teses e dissertações.
-
1. Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil
OBJECTIVES: To evaluate the effects of epoetin (EPO) alfa treatment on overall survival, event-free survival and response duration in patients with myelodysplastic syndrome (MDS) who were treated at a haematological referral centre in northeastern Brazil. METHODS: This was a retrospective cohort study of 36 patients diagnosed with MDS and treated with EPO
Clinics. Publicado em: 09/09/2019
-
2. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
Anemia is an inevitable complication of hemodialysis, and the primary cause is erythropoietin deficiency. After diagnosis, treatment begins with an erythropoiesis-stimulating agent (ESA). However, some patients remain anemic even after receiving this medication. This study aimed to investigate the factors associated with resistance to recombinant human eryth
Braz J Med Biol Res. Publicado em: 07/05/2018
-
3. Erythropoietin reduces storage lesions and decreases apoptosis indices in blood bank red blood cells
ABSTRACT Background: Recent evidence shows a selective destruction of the youngest circulating red blood cells (neocytolysis) trigged by a drop in erythropoietin levels. Objective: The aim of this study was to evaluate the effect of recombinant human erythropoietin beta on the red blood cell storage lesion and apoptosis indices under blood bank conditions.
Rev. Bras. Hematol. Hemoter.. Publicado em: 2016-02
-
4. PRELIMINARY MODELING OF AN INDUSTRIAL RECOMBINANT HUMAN ERYTHROPOIETIN PURIFICATION PROCESS BY ARTIFICIAL NEURAL NETWORKS
Abstract In the present study a preliminary neural network modelling to improve our understanding of Recombinant Human Erythropoietin purification process in a plant was explored. A three layer feed-forward back propagation neural network was constructed for predicting the efficiency of the purification section comprising four chromatographic steps as a func
Braz. J. Chem. Eng.. Publicado em: 2015-09
-
5. Resistance of dialyzed patients to erythropoietin
Resistance to recombinant human erythropoietin is a common condition in dialyzed patients with chronic kidney disease and is associated with more hospitalizations, increased mortality and frequent blood transfusions. The main cause of hyporesponsiveness to recombinant human erythropoietin in these patients is iron deficiency. However, a high proportion of p
Rev. Bras. Hematol. Hemoter.. Publicado em: 2015-06
-
6. Sociodemographic characteristics and clinical features of patients with adult polycystic kidney disease undergoing hemodialysis; Características sociodemográficas e aspectos clínicos de pacientes com doença renal policística do adulto submetidos a hemodiá
AIMS: To analyze the sociodemographic and clinical characteristics of patients with adult polycystic kidney disease admitted to hemodialysis services in Northwestern Paraná state, Brazil. METHODS: This was an observational, descriptive and retrospective longitudinal study. Medical records of patients with polycystic kidneys who initiated hemodialysis betwee
Publicado em: 08/05/2015
-
7. Potency Evaluation of Recombinant Human Erythropoietin in Brazil: Assessment of Reproducibility Using a Practical Approach
In this study, we compared the results of potency determination of recombinant human erythropoietin (rhEPO) obtained between 2010 and 2012 by the National Institute of Quality Control in Health (INCQS/Fiocruz), i.e., the National Control Laboratory (NCL), and by a manufacturer of rhEPO. In total, 47 different batches of commercially prepared rhEPO (alpha iso
Braz. arch. biol. technol.. Publicado em: 01/05/2015
-
8. Guidelines on the treatment of anemia of chronic renal failure using recombinant human erythropoietin: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira – 2014
Rev. Bras. Hematol. Hemoter.. Publicado em: 2014-12
-
9. Modelos para a produção de eritropoietina recombinante humana in vivo e in vitro com vetores plasmideais em ovinos / Models for the production of human recombinant erythropoietin in vivo and in vitro with plasmidial vectors in ovine
Some post-translational modifications are necessary for the production of biopharmaceutical proteins, such as recombinant human erythropoietin (rhEPO), with a good specific action and a high biological activity. These modifications are obtained only by bioreactors based on eukaryotic cell as mammary cells. Bioreactors, in vivo or in vitro, with this kind of
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 24/02/2011
-
10. Expression and analysis of the glycosylation properties of recombinant human erythropoietin expressed in Pichia pastoris
The Pichia pastoris expression system was used to produce recombinant human erythropoietin, a protein synthesized by the adult kidney and responsible for the regulation of red blood cell production. The entire recombinant human erythropoietin (rhEPO) gene was constructed using the Splicing by Overlap Extension by PCR (SOE-PCR) technique, cloned and expressed
Genetics and Molecular Biology. Publicado em: 08/07/2011
-
11. Antibody response following Hepatitis B vaccination in peritoneal dialysis patients: does normalized urea clearance matter?
OBJECTIVES: Data on the factors that contribute to the antibody response to hepatitis B virus vaccination in peritoneal dialysis patients are scarce. The current study was conducted on a group of peritoneal dialysis patients to learn how the response to hepatitis B virus vaccination varies according to the patient's clearance of urea normalized to total body
Clinics. Publicado em: 2011
-
12. Hemodialysis improves endothelial venous function in end-stage renal disease
The objective of the present study was to determine the acute effect of hemodialysis on endothelial venous function and oxidative stress. We studied 9 patients with end-stage renal disease (ESRD), 36.8 ± 3.0 years old, arterial pressure 133.8 ± 6.8/80.0 ± 5.0 mmHg, time on dialysis 55.0 ± 16.6 months, immediately before and after a hemodialysis session,
Publicado em: 2010